Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006122 · ClinicalTrials.gov registry record · Phase 2
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT01006122 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 95 participants.
The verdict
NCT01006122, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in EDS when treated with this compound compared to placebo in patients with narcolepsy is hypothesized.
Interventions
- DRUG Placebo
- DRUG PF-03654746
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01006122
The ClinicalTrials.gov registry entry for NCT01006122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01006122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01006122 about?
NCT01006122 is a clinical study titled "A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy". Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in EDS when treated with this co...
What is the current status of trial NCT01006122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2009-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01006122?
The interventions under investigation include: Placebo (DRUG), PF-03654746 (DRUG).
Who is sponsoring clinical trial NCT01006122?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.